IMA Group Acquires ProSys to Scale Global Aseptic Sampling Solutions

IMA Group has acquired a majority of shares in ProSys Sampling Systems Limited, strategically expanding its reach in the global bio-pharmaceutical sector.¹ IMA’s moves signal a more integrated approach to sourcing the specialized equipment required for sensitive sampling and isolation processes. The landscape of pharmaceuticals continues to shift toward major equipment providers consolidating specialized expertise to address the increasing demand for high-integrity aseptic and containment solutions.

How Does this Acquisition Impact the Availability of Containment Technologies?

ProSys has spent three decades establishing itself as a provider of specialized equipment to the bio-pharmaceutical market.¹ Under the new agreement, the company will continue to operate as an independent business, allowing for the maintenance of niche technical expertise while leveraging the broader resources of a global machinery organization.

What Benefits Arise from the Integration of these Specialized Technical Portfolios?

The alignment of these organizations aims to create a more comprehensive portfolio for aseptic and containment applications, which is essential for maintaining sterile environments and protecting operators during the production of potent compounds.¹ This synergy is designed to support the long-term growth of technical solutions available to the industry, ensuring that development facilities have access to the evolving knowledge required for complex sampling and containment tasks. Regarding the transition, leadership at ProSys stated in a press release,¹ "For ProSys, joining the IMA Group represents an excellent opportunity to support business development and long-term growth. We look forward to contributing our knowledge, in aseptic, containment and sampling technology to the combined portfolio and to becoming part of the IMA team, united by a shared business culture.”

How Else Is IMA Utilizing Mergers and Partnerships?

The shift toward specialized manufacturing solutions is increasingly accompanied by a focus on end-to-end efficiency, extending from the production floor to automated logistics.² Another partnership between the IMA Group and Cognex Corporation focuses on utilizing AI vision systems and specialized barcode readers to refine fulfillment processes. This collaboration is addressing the dual challenge of maintaining package integrity while meeting increasingly stringent sustainability regulations. The integration of advanced scanning technology ensures that product tracking remains accurate throughout the distribution chain, supporting complex global supply paths.

Why Is the Intersection of AI and Packaging Integrity Critical for the Pharmaceutical Supply Chain?

By utilizing AI for inspection, manufacturers can verify the quality of seals and reduce waste caused by excess void space.² This approach aligns with broader industry efforts to reduce plastic use and adhere to eco-friendly mandates. Regarding this transition, Simone Capponcelli, Sales Manager at IMA E-COMMERCE, stated in a press release,² “Customers want a solution that helps them meet sustainability goals by reducing their environmental impact, and they aren’t willing to take risks when it comes to quality or package integrity.” Ultimately, leveraging these automated tools allows for the scaling of operations while providing the reliability required for sensitive pharmaceutical shipments.

References

1. IMA. IMA acquires ProSys. Press Release. Feb 11, 2026.
2. IMA. IMA E-COMMERCE Partners with Cognex for Sustainable and Efficient Order Fulfillment. Press Release. May 15, 2025.